

1: Mazzanti R, Arena U, Tassi R. Hepatocellular carcinoma: Where are we? *World J Exp Med.* 2016 Feb 20;6(1):21–36. doi: 10.5493/wjem.v6.i1.21. Review. PubMed PMID: 26929917; PubMed Central PMCID: PMC4759352.

2: Fantappiè O, Sassoli C, Tani A, Nosi D, Marchetti S, Formigli L, Mazzanti R. Mitochondria of a human multidrug-resistant hepatocellular carcinoma cell line constitutively express inducible nitric oxide synthase in the inner membrane. *J Cell Mol Med.* 2015 Jun;19(6):1410–7. doi: 10.1111/jcmm.12528. PubMed PMID: 25691007; PubMed Central PMCID: PMC4459854.

3: Tassi R, Baldazzi V, Lapini A, Carini M, Mazzanti R. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events? *Clin Genitourin Cancer.* 2015 Apr;13(2):e101–5. doi: 10.1016/j.clgc.2014.08.009. PubMed PMID: 25450040.

4: Sardi I, Fantappiè O, la Marca G, Giovannini MG, Iorio AL, da Ros M, Malvagia S, Cardellicchio S, Giunti L, de Martino M, Mazzanti R. Delivery of doxorubicin across the blood–brain barrier by ondansetron pretreatment: a study in vitro and in vivo. *Cancer Lett.* 2014 Oct 28;353(2):242–7. doi: 10.1016/j.canlet.2014.07.018. PubMed PMID: 25079687.

5: Marchetti S, Pluim D, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JH. "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS–275,183". *Invest New Drugs.* 2014 Dec;32(6):1083–95. doi: 10.1007/s10637-014-0143-0. PubMed PMID: 25078948.

6: Bracarda S, Gernone A, Gasparro D, Marchetti P, Ronzoni M, Bortolus R, Fratino L, Basso U, Mazzanti R, Messina C, Tucci M, Boccardo F, Cartenì G, Pinto C, Fornarini G, Mattioli R, Procopio G, Chiuri V, Scotto T, Dondi D, Di

Lorenzo G.  
Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer. *Future Oncol.* 2014 May;10(6):975-83. doi: 10.2217/fon.13.256. PubMed PMID: 24295376.

7: Lin F, Marchetti S, Pluim D, Iusuf D, Mazzanti R, Schellens JH, Beijnen JH, van Tellingen O. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues. *Clin Cancer Res.* 2013 Apr 15;19(8):2084-95. doi: 10.1158/1078-0432.CCR-12-3105. PubMed PMID: 23461902.

8: Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JH. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA. *Invest New Drugs.* 2013 Oct;31(5):1125-35. doi: 10.1007/s10637-013-9923-1. Erratum in: *Invest New Drugs.* 2013 Jun;31(3):800. PubMed PMID: 23315030.

9: Baldazzi V, Tassi R, Lapini A, Lunghi A, Garofoli E, Caruso S, Carini M, Mazzanti R. Sunitinib-induced hyperparathyroidism: a possible mechanism to altered bone homeostasis. *Cancer.* 2012 Jun 15;118(12):3165-72. doi: 10.1002/cncr.26435. PubMed PMID: 21956360.

10: Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study. *Urol Oncol.* 2012 Sep;30(5):704-10. doi: 10.1016/j.urolonc.2010.07.015. PubMed PMID: 20884255.

11: Solazzo M, Fantappiè O, D'Amico M, Sassoli C, Tani A, Cipriani G, Bogani C, Formigli L, Mazzanti R. Mitochondrial expression and functional activity of

breast cancer resistance protein in different multiple drug-resistant cell lines.

Cancer Res. 2009 Sep 15;69(18):7235-42. doi: 10.1158/0008-5472.CAN-08-4315.

PubMed PMID: 19706772.

12: Mazzanti R, Platini F, Bottini C, Fantappiè O, Solazzo M, Tessitore L.

Down-regulation of the HGF/MET autocrine loop induced by celecoxib and mediated

by P-gp in MDR-positive human hepatocellular carcinoma cell line. Biochem

Pharmacol. 2009 Jul 1;78(1):21-32. doi: 10.1016/j.bcp.2009.03.013.

PubMed PMID:

19447220.

13: Kanduc D, Novello G, Mazzanti R. P-170 peptides with low similarity to the

human proteome: tracing an effective and safe biological way towards effective

and safe cancer chemotherapy. J Exp Ther Oncol. 2009;8(2):151-5.

PubMed PMID:

20192121.

14: Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH,

Mazzanti R, van Tellingen O, Schellens JH. Effect of the ATP-binding cassette

drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva)

disposition in in vitro and in vivo pharmacokinetic studies employing

Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice. Mol Cancer Ther. 2008

Aug;7(8):2280-7. doi: 10.1158/1535-7163.MCT-07-2250. PubMed PMID: 18723475.

15: Marchetti S, Oostendorp RL, Pluim D, van Eijndhoven M, van Tellingen O,

Schinkel AH, Versace R, Beijnen JH, Mazzanti R, Schellens JH. In vitro transport

of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance

protein, P-glycoprotein, and multidrug resistance protein 2. Mol Cancer Ther.

2007 Dec;6(12 Pt 1):3307-13. PubMed PMID: 18089724.

16: Mazzanti R, Gramantieri L, Bolondi L. Hepatocellular carcinoma: epidemiology

and clinical aspects. *Mol Aspects Med.* 2008 Feb-Apr;29(1-2):130-43.  
Review.  
PubMed PMID: 18061252.

17: Mazzanti R, Messerini L, Comin CE, Fedeli L, Ganne-Carrie N, Beaugrand M.  
Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients. *World J Gastroenterol.* 2007 Oct 7;13(37):5009-14. PubMed PMID: 17854145; PubMed Central PMCID: PMC4434626.

18: Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). *Oncologist.* 2007 Aug;12(8):927-41. Review. PubMed PMID: 17766652.

19: Fantappiè O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R.  
P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. *Cancer Res.* 2007 May 15;67(10):4915-23. PubMed PMID: 17510421.

20: Solazzo M, Fantappiè O, Lasagna N, Sassoli C, Nosi D, Mazzanti R. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. *Exp Cell Res.* 2006 Dec 10;312(20):4070-8. PubMed PMID: 17027968.

21: Bolondi L, Piscaglia F, Gatta A, Salerno F, Bernardi M, Ascione A, Ferrà O, Sacerdoti D, Visentin S, Trevisani F, Mazzanti R, Donati G, Arena U, Gentilini P; DOC (Decrease Of Complications in cirrhosis) Study Group.. Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis. *Clin Gastroenterol Hepatol.* 2006 Nov; 4(11):1395-402. PubMed PMID: 16931172.

22: Mazzanti R, Giulivi C. Coordination of nuclear- and mitochondrial-DNA encoded proteins in cancer and normal colon tissues. *Biochim Biophys Acta*. 2006 May-Jun;1757(5-6):618-23. PubMed PMID: 16730322.

23: Lasagna N, Fantappiè O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G, Ziche M, Mazzanti R. Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. *Cancer Res*. 2006 Mar 1;66(5):2673-82. PubMed PMID: 16510587.

24: Kanduc D, Geliebter J, Lucchese A, Mazzanti R, Mittelman A, Polimeno L, Ponzetto A, Santacroce R, Simone S, Sinigaglia E, Sinha AA, Tessitore L, Tiwari RK, Farber E. Gene therapy in cancer: the missing point. *J Exp Ther Oncol*. 2005;5(2):151-8. Review. PubMed PMID: 16471041.

25: Mazzanti R, Solazzo M, Fantappiè O, Elfering S, Pantaleo P, Bechi P, Cianchi F, Ettl A, Giulivi C. Differential expression proteomics of human colon cancer. *Am J Physiol Gastrointest Liver Physiol*. 2006 Jun;290(6):G1329-38. PubMed PMID: 16439467.

26: Fulignati C, Pantaleo P, Cipriani G, Turrini M, Nicastro R, Mazzanti R, Neri B. An uncommon clinical presentation of retroperitoneal non-Hodgkin lymphoma successfully treated with chemotherapy: a case report. *World J Gastroenterol*. 2005 May 28;11(20):3151-5. PubMed PMID: 15918208; PubMed Central PMCID: PMC4305858.

27: Mazzanti R, Arena U, Pantaleo P, Antonuzzo L, Cipriani G, Neri B, Giordano C, Lanini F, Marchetti S, Gentilini P. Survival and prognostic factors in patients with hepatocellular carcinoma treated by percutaneous ethanol injection: a 10-year experience. *Can J Gastroenterol*. 2004 Oct;18(10):611-8.

PubMed PMID:  
15497001.

28: Fantappiè O, Lodovici M, Fabrizio P, Marchettia S, Fabbroni V, Solazzo M, Lasagna N, Pantaleo P, Mazzanti R. Vitamin E protects DNA from oxidative damage in human hepatocellular carcinoma cell lines. *Free Radic Res.* 2004 Jul;38(7):751-9. PubMed PMID: 15453640.

29: Vannacci A, Giannini L, Passani MB, Di Felice A, Pierpaoli S, Zagli G, Fantappiè O, Mazzanti R, Masini E, Mannaioni PF. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of Guinea pig mast cells: involvement of nitric oxide and eicosanoids. *J Pharmacol Exp Ther.* 2004 Oct;311(1):256-64. PubMed PMID: 15187170.

30: Cianchi F, Cortesini C, Fantappiè O, Messerini L, Sardi I, Lasagna N, Perna F, Fabbroni V, Di Felice A, Perigli G, Mazzanti R, Masini E. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. *Clin Cancer Res.* 2004 Apr 15;10(8):2694-704. PubMed PMID: 15102673.

31: Cianchi F, Cortesini C, Fantappiè O, Messerini L, Schiavone N, Vannacci A, Nistri S, Sardi I, Baroni G, Marzocca C, Perna F, Mazzanti R, Bechi P, Masini E. Inducible nitric oxide synthase expression in human colorectal cancer: correlation with tumor angiogenesis. *Am J Pathol.* 2003 Mar;162(3):793-801. PubMed PMID: 12598314; PubMed Central PMCID: PMC1868089.

32: Daniele B, De Sio I, Izzo F, Capuano G, Andreana A, Mazzanti R, Aiello A, Vallone P, Fiore F, Gaeta GB, Perrone F, Pignata S, Gallo C; CLIP Investigators.. Hepatic resection and percutaneous ethanol injection as treatments of small hepatocellular carcinoma: a Cancer of the Liver Italian Program (CLIP 08) retrospective case-control study. *J Clin Gastroenterol.* 2003 Jan;36(1):63-7. PubMed PMID: 12488711.

33: Fantappiè O, Masini E, Sardi I, Raimondi L, Bani D, Solazzo M, Vannacci A, Mazzanti R. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. *Hepatology*. 2002 Apr; 35(4):843-52.  
PubMed PMID: 11915030.